Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes

Metabolic Syndrome and Related Disorders

Volumn 11, Issue 4, 2013, Pages 251-255

  Ganesan, Shobana ^a   Ito, Matthew K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; GLUCOSE TRANSPORTER 4; PRAVASTATIN; SIMVASTATIN; UBIDECARENONE;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CELL STRUCTURE; CONTROLLED STUDY; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DIABETES MELLITUS; DRUG INTERACTIONS; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; MICE; PRAVASTATIN; SIMVASTATIN; UBIQUINONE;

EID: 84880423901     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2012.0177     Document Type: Article

References (18)

1. Lardizabal JA, Deedwania PC. Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag 2010;5:843-853.
2. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;27:735-742.
3. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diabetes Care 2009;32:1924-1929.
4. US Food and Drug Administration. Consumer updates 2012. Available atwww.fda.gov/ForConsumers/ConsumerUpdates/ ucm293330.htm/. AccessedMarch 1, 2013.
5. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderatedose statin therapy: A meta-analysis. JAMA 2011;22: 2556-2564.
6. Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Res Clin Pract, 2010; 87:98-107.
7. Ma T, Mu-Hsin C, Tien L, et al. The long-term effect of statins on risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidemia. Drugs Aging 2012;29:45-51.
8. Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab 2007;5:237-252.
9. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001;507:357-361.
10. Takaguri A, Satoh K, Itagaki M, et al. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci 2008; 107:80-89.
11. Muraki A, Miyashita K, Mitsuishi M, et al. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J Appl Physiol 2012; 113:479-486.
12. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: Possible role in insulin resistance. Science 2003;300:1140-1142.
13. Ito MK. Dyslipidemia: Management using optimal lipidlowering therapy. Ann Pharmacother 2012;46:1368-1381.
14. Hiramitsu S, Ishiguro Y, Matsuyama H, et al. The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb 2010;17:106-114.
15. Dagli N, Yavuzkir M, Karaca I. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 2007;30:230-235.
16. Yang SJ, Choi JM, Kim L, et al. Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes. Biochem Biophys Res Commun 2011;407:153-157.
17. Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. Ochsner J 2010; 10:16-21.
18. Petersen KF, Dufour S, Shulman GI. Decreased insulinstimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med 2005:2:e233.